AIM: To investigate the immunogenicity of a novel DNA vaccine, pSW3891/HBc, based on HBV core gene in Balb/c mice. METHODS: A novel DNA vaccine, pSW3891/HBc, encoding HBV core gene was constructed using a vector plasmid pSW3891. Balb/c mice were immunized with either pSW3891/HBc or empty vector DNA via gene gun. IgG anti-HBc responses in mouse sera were demonstrated by ELISA. Specific cytotoxicity of cytotoxic T lymphocytes (CTLs) of mice was quantitatively measured by lactate dehydrogenase release assay. RESULTS: HBcAg was expressed effectively in 293T cell line transiently transfected with pSW3891/HBc. Strong IgG anti-HBc responses were elicited in mice immunized with pSW3891/HBc. The end-point titers of anti-HBc reached the highest 1:97,200, 4 wk after the third immunization. The specific CTL killing with the highest specific lysis reached 73.25% at effector:target ratio of 20:1 in mice that received pSW3891/HBc DNA vaccine. CONCLUSION: pSW3891/HBc vaccination elicits specific anti-HBc response and induces HBc-specific CTL response in immunized Balb/c mice.
AIM: To investigate the immunogenicity of a novel DNA vaccine, pSW3891/HBc, based on HBV core gene in Balb/c mice. METHODS: A novel DNA vaccine, pSW3891/HBc, encoding HBV core gene was constructed using a vector plasmid pSW3891. Balb/c mice were immunized with either pSW3891/HBc or empty vector DNA via gene gun. IgG anti-HBc responses in mouse sera were demonstrated by ELISA. Specific cytotoxicity of cytotoxic T lymphocytes (CTLs) of mice was quantitatively measured by lactate dehydrogenase release assay. RESULTS: HBcAg was expressed effectively in 293T cell line transiently transfected with pSW3891/HBc. Strong IgG anti-HBc responses were elicited in mice immunized with pSW3891/HBc. The end-point titers of anti-HBc reached the highest 1:97,200, 4 wk after the third immunization. The specific CTL killing with the highest specific lysis reached 73.25% at effector:target ratio of 20:1 in mice that received pSW3891/HBc DNA vaccine. CONCLUSION: pSW3891/HBc vaccination elicits specific anti-HBc response and induces HBc-specific CTL response in immunized Balb/c mice.
Authors: C Ferrari; A Penna; A Bertoletti; A Valli; A D Antoni; T Giuberti; A Cavalli; M A Petit; F Fiaccadori Journal: J Immunol Date: 1990-11-15 Impact factor: 5.422
Authors: Y S Lee; S J Yoon; T K Kwon; Y H Kim; J H Woo; M H Suh; S I Suh; W K Baek; H J Kim; S Y Ahn; B K Choe; J W Park Journal: Immunol Lett Date: 2001-08-01 Impact factor: 3.685
Authors: M J Roy; M S Wu; L J Barr; J T Fuller; L G Tussey; S Speller; J Culp; J K Burkholder; W F Swain; R M Dixon; G Widera; R Vessey; A King; G Ogg; A Gallimore; J R Haynes; D Heydenburg Fuller Journal: Vaccine Date: 2000-11-22 Impact factor: 3.641
Authors: M C Jung; H M Diepolder; U Spengler; E A Wierenga; R Zachoval; R M Hoffmann; D Eichenlaub; G Frösner; H Will; G R Pape Journal: J Virol Date: 1995-06 Impact factor: 5.103
Authors: A Penna; F V Chisari; A Bertoletti; G Missale; P Fowler; T Giuberti; F Fiaccadori; C Ferrari Journal: J Exp Med Date: 1991-12-01 Impact factor: 14.307
Authors: N Obeng-Adjei; D K Choo; J Saini; J Yan; P Pankhong; A Parikh; J S Chu; D B Weiner Journal: Cancer Gene Ther Date: 2012-10-05 Impact factor: 5.987